Synthesis and Structure–Activity Analysis of Icaritin Derivatives as Potential Tumor Growth Inhibitors of Hepatocellular Carcinoma Cells
Journal of Natural Products · 2023
DOI: 10.1021/acs.jnatprod.2c00908 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Natural Products, 2023. Verfasst von Jichong Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Computational Chemistry Based Natural Antitumor Drug Research & Development, Liaoning Province, School of Traditional Chinese Mater…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Natural Science Foundation of Liaoning Province, Department of Education of Liaoning Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
The prenylated flavonoid icaritin (ICT, 1), a new drug for treating advanced hepatocellular carcinoma (HCC), was selected as a template to develop more potent inhibitors. An initial semisynthetic modification of ICT was performed to obtain a structure-activity relationship (SAR), which indicated that the cytotoxicity is enhanced by OH-3 rhamnosylation and that OH-7 is an important modification site. Based on the results of the SAR study, 46 N-containing ICT derivatives were synthesized and evaluated as the anti-HCC inhibitors. The results showed that most of the derivatives produced inhibited three HCC cell lines used (Hep3B, HepG2 and SMMC-7721). The modification strategy was validated by 3D-QSAR, which provided information for the further design and optimization of ICT. The most potent compound, 11c, exhibited IC50 values of 7.6 and 3.1 μM against HepG2 and SMMC-7721 cells, respectively, which were more potent than those of ICT and sorafenib, respectively. Further mechanistic studies indicated that 11c caused arrest at the G0/G1 phase in the cell cycle and induced cell apoptosis in HepG2 and SMMC-7721 cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Computational Chemistry Based Natural Antitumor Drug Research & Development, Liaoning Province, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People…
- Jilin Yizheng Pharmaceutical Group Co., Ltd., Siping, Jilin Province136001, People's Republic of China.
ORCID-Profile: Qingbo Liu, Shao-Jiang Song
Förderung
- Natural Science Foundation of Liaoning Province
- Department of Education of Liaoning Province
- National Natural Science Foundation of China
Zitieren
APA
Li, J., Shen, S., Liu, Z., Zhao, H., Liu, S., Liu, Q., Yao, G. D., & Song, S. J. (2023). Synthesis and Structure–Activity Analysis of Icaritin Derivatives as Potential Tumor Growth Inhibitors of Hepatocellular Carcinoma Cells. Journal of Natural Products. https://doi.org/10.1021/acs.jnatprod.2c00908
Vancouver
Li J, Shen S, Liu Z, Zhao H, Liu S, Liu Q, et al. Synthesis and Structure–Activity Analysis of Icaritin Derivatives as Potential Tumor Growth Inhibitors of Hepatocellular Carcinoma Cells. Journal of Natural Products. 2023. doi:10.1021/acs.jnatprod.2c00908
BibTeX
@article{Li2023,
author = {Li, Jichong and Shen, Shuai and Liu, Zijian and Zhao, Hongwei and Liu, Siyang and Liu, Qingbo and Yao, Guo-Dong and Song, Shao-Jiang},
title = {Synthesis and Structure–Activity Analysis of Icaritin Derivatives as Potential Tumor Growth Inhibitors of Hepatocellular Carcinoma Cells},
journal = {Journal of Natural Products},
year = {2023},
doi = {10.1021/acs.jnatprod.2c00908}
}
EUVIMED